Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer
A Phase II Trial of Prostate Stereotactic Radiotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Jonathan YH Teh
- Phone Number: 63214204
- Email: jonathan.Teh.Y.H@nccs.com.sg
Study Contact Backup
- Name: Sheena XF Tan
- Phone Number: 63214204
- Email: Sheena.Tan.X.F@nccs.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169610
- Recruiting
- National Cancer Centre Singapore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of adenocarcinoma of the prostate
- History/physical examination with digital rectal examination of the prostate within 60 days prior to registration
- Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores 2-7
- Clinical stage T1-2b (DRE) (AJCC 7th edition) within 90 days of registration
- PSA < 20 ng/mL within 60 days prior to registration. PSA should not be obtained within 10 days after prostate biopsy. (Every effort should be made to obtain all serum PSA values obtained in the 1 year prior to treatment to allow for calculation of PSA kinetics.)
- Not more than one intermediate risk factor (T2b/GS7/PSA 10-20)
- Zubrod Performance Status 0-1 within 60 days prior to registration
- Age ≥ 21
- Patient must be able to provide study-specific informed consent prior to study entry.
- Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
Exclusion Criteria:
- Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years. (For example, carcinoma of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed)
- T-stage ≥ T2c on staging MRI
- Evidence of distant metastases
- Regional lymph node involvement
- Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer
- Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
- Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or surgical castration (orchiectomy)
- Use of finasteride within 30 days prior to registration. PSA should not be obtained prior to 30 days after stopping finasteride.
- Use of dutasteride within 90 days prior to registration. PSA should not be obtained prior to 90 days after stopping dutasteride.
- Previous or concurrent cytotoxic chemotherapy for prostate cancer
Severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol. (Patients on Coumadin or other blood thinning agents are eligible for this study.)
- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Stereotactic Body Radiotherapy
An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
|
IMRT or similar techniques that use inverse treatment planning
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The rate of late severe GI and GU toxicities
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The rate of late severe GI and GU toxicities
Time Frame: 1 and 5 years
|
1 and 5 years
|
|
The rate of acute severe GI and GU toxicities
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
PSA failure-free survival
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Disease-free survival (DFS)
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Time to local progression
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Time to distant and/or regional failure
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Disease-specific survival
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Freedom from biochemical recurrence (FFBR)
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
Overall survival (OS)
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
|
The change in quality of life outcomes from baseline
Time Frame: 1, 2 and 5 years
|
1, 2 and 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Melvin LK Chua, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NCCS DRO SBRT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.